vimarsana.com
Home
Live Updates
Neurologists Report Frustration with Efficacy and Logistical
Neurologists Report Frustration with Efficacy and Logistical
Neurologists Report Frustration with Efficacy and Logistical Issues Around Eisai/Biogen's ... | Region
EXTON, PA, Feb. 22, 2024 (GLOBE NEWSWIRE) -- The 2023 announcement of newly approved disease-modifying therapy (DMT) Leqembi (lecanemab) for Alzheimer’s Disease (AD) sparked eager anticipation within both the medical
Related Keywords
Alissa Algarin ,
Eli Lilly ,
Spherix Network ,
Linkedin ,
Dynamix ,
Global Insight ,
Launch Dynamix ,
Global Insights ,
Spherix Global Insights ,
Spherix Global Insight ,
Insights Director ,
Neurology Spherix Global Insights ,
Region ,